Levetiracetam monotherapy for late poststroke seizures in the elderly.

Department of Neurology, Ankara Research and Training Hospital, Ministry of Health, Ankara, Turkey.
Epilepsy & Behavior (Impact Factor: 1.84). 07/2008; 13(3):542-4. DOI: 10.1016/j.yebeh.2008.04.025
Source: PubMed

ABSTRACT Stroke is the most common cause of seizures in the elderly. Antiepileptic drugs are used to treat most patients with late poststroke seizures. The aim of this study was to evaluate the efficacy and tolerability of levetiracetam (LEV) in patients aged 60 or older with late-onset poststroke seizures. This prospective study evaluated patients 60 years of age or older, who had at least two late-onset poststroke seizures and were given LEV monotherapy. Demographic data and seizure and stroke characteristics were recorded. Outpatient visits were made after 2, 4, 6, 9, and 12 months and every 3 months thereafter, and the effectiveness and tolerability of LEV were investigated. Thirty-four patients with a mean age of 69.76+/-6.41 were included in this study. Average seizure frequency before treatment was 3.61+/-3.02/month. Mean follow-up time was 17.68+/-3.24 months. At daily doses of 1000-2000 mg, 82.4% of the patients were seizure free, and 7 patients (20.6%) had side effects. LEV was discontinued in one patient because of severe somnolence. Two patients were switched to another antiepileptic drug because of uncontrolled seizures despite an increase in dose up to 3000 mg/day. LEV monotherapy can be effective and well tolerated in elderly patients with late-onset poststroke seizures.

  • [Show abstract] [Hide abstract]
    ABSTRACT: La confusion mentale, fréquente chez le sujet âgé hospitalisé, réalise un syndrome clinique peu spécifique, généralement secondaire à une pathologie générale aiguë. L’épilepsie, dont la prévalence croît significativement après 60 ans, fait néanmoins partie des étiologies à rechercher, parce qu’une confusion peut être postcritique ou due à un état de mal non convulsif. La confusion partage, par ailleurs, de nombreux déterminants avec les crises d’épilepsie dites situationnelles, et la tolérance cognitive ou comportementale des anticonvulsivants est inégale. Confusion is a common feature in the hospitalized elderly and consists of a relatively non-specific syndrome, usually due to a general pathology. Nevertheless, the prevalence of epilepsy significantly increases after the age of sixty, and this aetiology must be searched for in the case of acute confusion, as this can be a postictal state, or non-convulsive status epilepticus. Moreover, confusion and acute symptomatic seizures share numerous factors, and cognitive and behavioural tolerability of antiepileptic drugs is fairly variable.
    Les cahiers de l année gérontologique 01/2009; 1(2):118-122.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common hereditary small-vessel disease. CADASIL is caused by mutations in the NOTCH3 gene on chromosome 19; its global incidence and prevalence are unknown, likely because of under-diagnosis. CADASIL is a multisystemic disease, but its main clinical manifestations are related to the involvement of the brain. Very few controlled studies have been specifically performed on therapeutic interventions for CADASIL and its clinical manifestations. Areas covered: Evidence is reviewed about possible effects of controlling risk factors for the disease, and about treatment of most common clinical manifestations: migraine, TIA/stroke, psychiatric disturbances and epilepsy, cognitive impairment and dementia. Expert opinion: Correction of risk factors, and in particular hypertension, seems to be mandatory for reducing risk of stroke. Antiplatelet agents in secondary prevention in CADASIL might be recommended for secondary but not for primary prevention. Antiepileptic drugs seem to be the best choice for prophylaxis of migraine and MA, when needed. Psychiatric symptoms should be treated with conventional drugs, after reaching correct clinical diagnosis. Treatment of cognitive impairment and dementia with cholinesterase inhibitors may be effective on executive functions, but no conclusive data are available about its usefulness.
    Expert Opinion on Orphan Drugs. 08/2013; 1(9).
  • Source
    01/2013: pages 189-200; , ISBN: 978-90-81054-26-3


Available from
May 20, 2014